DSCAM and breast cancer: Previous studies have found that DSCAM-AS1 is highly specific to luminal breast cancer and is directly regulated by estrogen receptor α (ERα), playing vital roles in tumor proliferation, invasion, and tamoxifen resistance [22–24].